bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: N O S A J J M A M F J
2016: D N

  Health Highlights: Oct. 6, 2017

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

Cigna Says No to OxyContin

Most OxyContin prescriptions will no longer be covered in Cigna group health plans starting in January, the insurance giant announced.

The move is an attempt to help stem the opioid epidemic that has spread across the United States, company officials said.

"Our focus is on helping customers get the most value from their medications -- this means obtaining effective pain relief while also guarding against opioid misuse," Cigna Chief Pharmacy Officer Jon Maesner said in a statement.

Although OxyContin won't be an option for Cigna customers unless a doctor deems it "medically necessary," the company said it has signed a contract with the maker of another opioid, known as Xtampza ER.

Xtampza is "an [OxyContin] equivalent with abuse-deterrent properties," the company said. "Xtampza ER's abuse-deterrent platform allows the product to maintain its extended-release profile even when cut, crushed or chewed."

OxyContin also has abuse-deterrent properties, CNN reported, such as being more difficult to crush. One study did find that Xtampza was harder to abuse than OxyContin, but that research was conducted by Xtampza's manufacturer, Collegium Pharmaceutical, according to the news service.

One drug safety expert noted that abuse deterrence has limitations.

"People don't recognize that just because they are harder to tamper with doesn't make them any less addictive or any more effective in chronic non-cancer pain," Dr. Caleb Alexander, director of the Johns Hopkins Center for Drug Safety and Effectiveness, told CNN.

Alexander added that financial factors may have played a part in Cigna's decision to drop OxyContin.

But Dr. Charles Argoff, president of the American Academy of Pain Medicine Foundation, told CNN, "We are going down a very bad slippery slope if we allow payers to only make decisions solely on financial grounds."

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=727284

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Pain
Drug Toxicity
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact